Enobosarm
QUALITY
Veru Inc · Phase 2 · Completed · Enrollment 168
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily | n/r | n/r | n/r | n/r |
| Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily | n/r | n/r | n/r | n/r |
| GLP-1 receptor agonist and Placebo QD by mouth (PG) daily | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily: endpoint not reported
- Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily: endpoint not reported
- GLP-1 receptor agonist and Placebo QD by mouth (PG) daily: endpoint not reported